Comparison · NCT01979536-deaths
Arm BV (Brentuximab Vedotin, Combination Chemotherapy) vs Arm CZ (Crizotinib, Combination Chemotherapy): deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm BV (Brentuximab Vedotin, Combination Chemotherapy) vs Arm CZ (Crizotinib, Combination Chemotherapy): deaths from any cause. Trial comparisons, record NCT01979536-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01979536-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0441 | 0.0151 | 0.122 | wilson | |
| Risk in group 2 | 0.0441 | 0.0151 | 0.122 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.083 | 0.083 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1 | 0.209 | 4.78 | log | |
| Odds ratio, group 1 over group 2 | 1 | 0.195 | 5.14 | log | |
| Number needed to harm | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm BV (Brentuximab Vedotin, Combination Chemotherapy) | COURSE A (CYCLES 1, 3, AND 5): Patients receive brentuximab vedotin IV over 30 minutes on day 1, dexamethasone PO BID or IV on days 1-5, ifosfamide IV over 60 minutes on days 1-5, methotrexate IV over 3 hours on day 1, cytarabine IV over 1-30 minutes every 12 hours for 4 doses on days 4 and 5, and etoposide IV over 2 hours on days 4 and 5.~COURSE B (CYCLES 2, 4, AND 6): Patients receive brentuximab vedotin, dexamethasone, and methotrexate as in Arm BV, Course A. Patients also receive cyclophosphamide IV over 15-30 minutes on days 1-5 and doxorubicin hydrochloride IV over 1-15 minutes on days 4 and 5.~Brentuximab Vedotin: Given IV~Cyclophosphamide: Given IV~Cytarabine: Given IT and IV~Dexamethasone: Given PO or IV~Doxorubicin Hydrochloride: Given IV~Etoposide: Given IV~Ifosfamide: Given IV~Methotrexate: Given IT and IV | 3 | 68 | EG000 |
| Group 2 | Arm CZ (Crizotinib, Combination Chemotherapy) | COURSE A (CYCLES 1, 3, AND 5): Patients receive crizotinib PO BID on days 1-21 and dexamethasone, ifosfamide, methotrexate, cytarabine, and etoposide as in Arm BV, Course A.~COURSE B (CYCLES 2, 4, AND 6): Patients receive crizotinib as in Arm CZ, Course A and dexamethasone, cyclophosphamide, methotrexate, and doxorubicin hydrochloride as in Arm BV, Course B.~Crizotinib: Given PO~Cyclophosphamide: Given IV~Cytarabine: Given IT and IV~Dexamethasone: Given PO or IV~Doxorubicin Hydrochloride: Given IV~Etoposide: Given IV~Ifosfamide: Given IV~Methotrexate: Given IT and IV | 3 | 68 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- Enrollment up to 5 years after enrollment
Source ClinicalTrials.gov
Trial
- Title
- Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
- NCT number
- NCT01979536
- Phases
- PHASE2
- Conditions
Anaplastic Large Cell Lymphoma, ALK-Positive, Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma
- Interventions
- Brentuximab Vedotin, Crizotinib, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Methotrexate
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2022-07-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01979536?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01979536-deaths